FY2025 Earnings Forecast for ALUR Issued By Chardan Capital

Allurion Technologies Inc. (NYSE:ALUR) – Chardan Capital increased their FY2025 earnings per share estimates for Allurion Technologies in a report released on Monday, March 24th. Chardan Capital analyst K. Nakae now forecasts that the company will post earnings of ($4.39) per share for the year, up from their prior forecast of ($4.82). Chardan Capital currently has a “Neutral” rating and a $2.50 target price on the stock. The consensus estimate for Allurion Technologies’ current full-year earnings is ($9.96) per share.

Separately, Roth Mkm restated a “buy” rating and issued a $16.00 price objective on shares of Allurion Technologies in a research note on Friday, March 21st.

Allurion Technologies Trading Up 4.1 %

Shares of NYSE ALUR opened at $3.25 on Thursday. The firm has a market capitalization of $15.57 million, a price-to-earnings ratio of -0.27 and a beta of -0.59. Allurion Technologies has a one year low of $2.15 and a one year high of $98.75. The business has a fifty day simple moving average of $4.01 and a 200 day simple moving average of $9.84.

Allurion Technologies (NYSE:ALUR) last issued its quarterly earnings results on Wednesday, March 26th. The company reported ($7.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.00) by ($2.00). The company had revenue of $5.59 million during the quarter, compared to analysts’ expectations of $5.60 million.

Hedge Funds Weigh In On Allurion Technologies

A hedge fund recently raised its stake in Allurion Technologies stock. Geode Capital Management LLC boosted its stake in shares of Allurion Technologies Inc. (NYSE:ALUR) by 40.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 516,330 shares of the company’s stock after acquiring an additional 149,484 shares during the quarter. Geode Capital Management LLC owned 0.80% of Allurion Technologies worth $317,000 as of its most recent SEC filing. 21.39% of the stock is currently owned by institutional investors and hedge funds.

About Allurion Technologies

Allurion Technologies Inc focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite.